AVITA Medical (RCEL) Stock Overview
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RCEL Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.96 |
| 52 Week High | US$14.16 |
| 52 Week Low | US$3.60 |
| Beta | 1.64 |
| 1 Month Change | -33.11% |
| 3 Month Change | -33.78% |
| 1 Year Change | -61.89% |
| 3 Year Change | -20.96% |
| 5 Year Change | -81.61% |
| Change since IPO | -84.16% |
Recent News & Updates
Recent updates
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Aug 10Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
May 29
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
Mar 06Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?
Dec 30AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 03AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Oct 04AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 18Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?
Jun 18Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding
Apr 12AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%
Feb 02The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%
Oct 20Avita Medical appoints James Corbett as CEO
Sep 29AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal
Sep 12Avita's burn therapy Recell gets insurance coverage in Japan following approval
Sep 01Shareholder Returns
| RCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -25.7% | -0.1% | -0.1% |
| 1Y | -61.9% | 2.6% | 16.6% |
Return vs Industry: RCEL underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: RCEL underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RCEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RCEL's weekly volatility has increased from 14% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 260 | Cary Vance | avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
AVITA Medical, Inc. Fundamentals Summary
| RCEL fundamental statistics | |
|---|---|
| Market cap | US$125.63m |
| Earnings (TTM) | -US$51.57m |
| Revenue (TTM) | US$74.88m |
Is RCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCEL income statement (TTM) | |
|---|---|
| Revenue | US$74.88m |
| Cost of Revenue | US$11.77m |
| Gross Profit | US$63.11m |
| Other Expenses | US$114.68m |
| Earnings | -US$51.57m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 84.28% |
| Net Profit Margin | -68.87% |
| Debt/Equity Ratio | -327.5% |
How did RCEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 05:37 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVITA Medical, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |